Prospective cardiotoxicity screening during tyrosine kinase inhibitor therapy for renal cell carcinoma: An institutional experience
R. M. Witteles , L. C. Harshman , M. Telli , S. Srinivas
Journal of Clinical Oncology 27 ( 15_suppl) e16003 -e16003
1
2009
Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age
L. C. Harshman , G. Bepler , Z. Zheng , J. P. Higgins
Journal of Clinical Oncology 27 ( 15_suppl) e16021 -e16021
2009
Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001.
L. C. Harshman , A. McMillan , S. Srinivas
Journal of Clinical Oncology 28
1
2010
The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).
M. Y. Al-Marrawi , B. I. Rini , L. C. Harshman , G. A. Bjarnason
Journal of Clinical Oncology 29 4555 -4555
14
2011
External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy.
D. Y. C. Heng , W. Xie , L. C. Harshman , G. A. Bjarnason
Journal of Clinical Oncology 29 4560 -4560
13
2011
The economic and clinical costs of chronic kidney disease following radical and partial nephrectomy in the management of small renal masses.
S. L. Chang , L. E. Cipriano , L. C. Harshman , B. I. Chung
Journal of Clinical Oncology 29 353 -353
2011
Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC)
L. C. Harshman , C. J. Kuo , S. Srinivas
Journal of Clinical Oncology 26 16096 -16096
1
2008
A phase II trial of calcitrol and naproxen in recurrent prostate cancer
S. Srinivas , L. C. Harshman , D. R. Feldman
Journal of Clinical Oncology 26 16103 -16103
2008
ERCC1 and RRM1 expression patterns in synchronous primary and metastatic urothelial cancer lesions.
L. C. Harshman , S. Manda , D. E. Hansel , J. McKenney
Journal of Clinical Oncology 29
2011
Association of body mass index (BMI) with progression-free survival (PFS) in patients with advanced renal cell cancer (RCC) treated with targeted therapies.
J. Dhaliwal , H. S. Gill , B. I. Chung , L. C. Harshman
Journal of Clinical Oncology 29
2011
Effect of fulvestrant on PSA doubling time in patients with castration-resistant prostate cancer (CRPC).
S. Srinivas , L. C. Harshman , D. Feldman
Journal of Clinical Oncology 28
2010
Non-clear cell renal cell carcinoma, part 1: histology.
Toni K. Choueiri , Michelle S. Hirsch , Lauren C. Harshman , Loana B. Valenca
Clinical advances in hematology & oncology 13 ( 5) 308 -313
11
2015
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Daniel P. Petrylak , Sanjeev Mariathasan , Jean-Pierre Delord , Thomas Powles
Clinical Cancer Research
1
2021
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Ronan Flippot , Toni K. Choueiri , Natalie Vokes , Petra Ross-Macdonald
Nature Communications 12 ( 1) 808 -808
4
2021
Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Lauren C. Harshman , Wanling Xie , Raphael B. Moreira , Dominick Bossé
Cancer 124 ( 5) 925 -933
16
2018
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer
Alberto Martini , Rachel Jia , Bart S. Ferket , Nikhil Waingankar
Cancer 125 ( 18) 3155 -3163
9
2019
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Matthew D. Galsky , Sumanta K. Pal , Simon Chowdhury , Lauren C. Harshman
Cancer 121 ( 15) 2586 -2593
103
2015
Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?
Lauren C. Harshman
Cancer 122 ( 13) 1966 -1970
4
2016
Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.
Cécile Vicier , Lillian Werner , Jonathan Chipman , Lauren C. Harshman
Clinical Genitourinary Cancer 17 ( 1) 32 -37
4
2019
A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma
Lauren C. Harshman , Sarah Barbeau , Alex McMillian , Sandy Srinivas
Clinical Genitourinary Cancer 11 ( 2) 100 -106
22
2013